Influx Healthtech (NSE:INFLUX) EBIT: ₹274 Mil (TTM As of Mar. 2026)


NSE:INFLUX Influx Healthtech Ltd NSE:INFLUX
21 GF Score
Price ₹301.10
! 4 Warning Signs
View Full Analysis

What is Influx Healthtech EBIT?

Influx Healthtech NSE:INFLUX +2.90% 21 EBIT is ₹274 Mil as of Mar. 2026. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Influx Healthtech's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was ₹143 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹274 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Influx Healthtech's annualized ROC % for the quarter that ended in Mar. 2026 was 28.91%. Influx Healthtech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 54.78%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Influx Healthtech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 4.15%.

Influx Healthtech  (NSE:INFLUX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Influx Healthtech's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=262.022 * ( 1 - 25.65% )/( (576.766 + 771.151)/ 2 )
=194.813357/673.9585
=28.91 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1135.402 - 193.018 - ( 365.618 - max(0, 232.918 - 825.585+365.618))
=576.766

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1237.03 - 191.226 - ( 274.653 - max(0, 227.116 - 814.628+274.653))
=771.151

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Influx Healthtech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=286.826/( ( (247.358 + max(216.115, 0)) + (310.213 + max(273.51, 0)) )/ 2 )
=286.826/( ( 463.473 + 583.723 )/ 2 )
=286.826/523.598
=54.78 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(340.988 + 106.286 + 1.759) - (193.018 + 0 + 39.9)
=216.115

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(337.804 + 159.327 + 3.495) - (191.226 + 0 + 35.89)
=273.51

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Influx Healthtech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=274.147/6604.967
=4.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech EBIT Related Terms

Influx Healthtech EBIT Historical Data

* Premium members only.

The historical data trend for Influx Healthtech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech EBIT Chart

Influx Healthtech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
EBIT
60.11 97.46 151.04 178.80 274.15

Influx Healthtech Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
EBIT Get a 7-Day Free Trial 0.00 78.66 100.14 130.73 143.41

NSE:INFLUX vs ZTS, UTHR: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Influx Healthtech EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Influx Healthtech's EV-to-EBIT falls into.


NSE:INFLUX
21GF Score
Influx Healthtech Ltd NSE:INFLUX
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Influx Healthtech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was ₹274 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ₹274 Mil mean?
Influx Healthtech (NSE:INFLUX) has a EBIT of ₹274 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Influx Healthtech.
Is Influx Healthtech's EBIT too high?
Influx Healthtech's current EBIT is ₹274 Mil. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's EBIT compare to ZTS and UTHR?
Influx Healthtech's EBIT of ₹274 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Influx Healthtech. Influx Healthtech's current EBIT is ₹274 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current EBIT of ₹274 Mil. The current EBIT is ₹274 Mil. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current EBIT is ₹274 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Influx Healthtech Business Description

Address Plot No. 856, 109, Ghanshyam Enclave Premises Co-op Society, Behind Laljipada Police Chowky, Kandivali West, Mumbai, MH, IND, 400067
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score

Get the complete analysis for NSE:INFLUX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹301.10
Price